{
    "RADCURE-3746": {
        "recruit-recruiter": "1. Radiation Oncologist - Your expertise is strictly limited to radiation therapy planning and dosing for head and neck squamous cell carcinoma, especially HPV-negative cases involving the floor of mouth. - Hierarchy: Radiation Oncologist",
        "question": "Age: 63.8, Sex: Male, ECOG PS: ECOG 1, Smoking PY: 20, Smoking Status: Current, Ds Site: Lip & Oral Cavity, Subsite: Floor of Mouth, T: T4a, N: N1, M : M0, Stage: IVA, Path: Squamous Cell Carcinoma, HPV: none, Tx Modality: RT alone, Chemo? : none, Dose: 70.0, Fx: 35, Local: none, Regional: none, Distant: none, 2nd Ca: none, ContrastEnhanced: 1\nAnswer: ",
        "think-initial_assessment-radiation oncologist": "<think> Okay, let's break this down. The patient is a 63.8-year-old male with a current smoking history of 20 pack-years. His ECOG PS is 1, which means he's restricted in physically strenuous activity but can do light work. The tumor is in the floor of the mouth, classified as T4a, N1, M0, stage IVA squamous cell carcinoma. HPV status is negative. He received radiation therapy alone at 70 Gy in 35 fractions, no chemo. No local, regional, or distant recurrences noted, and no second cancers.\n\nFirst, considering the primary factors affecting prognosis in head and neck cancers. HPV-negative status is a big one here. HPV-positive tumors generally have better outcomes, so this being negative is a negative prognostic indicator. Then there's the smoking history. Current smoker with 20 pack-years—smoking is known to worsen outcomes, both in terms of treatment response and overall survival. \n\nT4a tumor suggests a large primary lesion invading adjacent structures, which is more challenging to control locally. N1 indicates a single ipsilateral lymph node ≤3 cm. Stage IVA is locally advanced but non-metastatic. The treatment here was RT alone without chemotherapy. Current standard for locally advanced head and neck cancer, especially in non-HPV cases, often combines chemoradiation to improve outcomes. Using RT alone might be due to patient factors (maybe comorbidities or refusal of chemo), but in this case, no chemo was given. That could impact survival negatively compared to combined modality.\n\nThe dose of 70 Gy in 35 fractions is standard (2 Gy per fraction), so adequate in terms of dosing. However, without concurrent chemo, the control rates might be lower. Also, the floor of mouth location—some subsites have different outcomes, but I'm not sure if this specific subsite has a particular prognostic significance beyond T and N staging. \n\nConsidering all these factors: HPV-negative, current smoker, T4a, N1, stage IVA, RT alone. Even without recurrence noted, the overall survival might be lower compared to patients with similar stages receiving combined therapy. Studies show that in HPV-negative patients, especially with smoking, survival is worse. For example, in RTOG trials, the addition of chemo improves locoregional control and survival. Since this patient didn't get chemo, maybe higher risk of recurrence, even if not noted yet. Also, age 63.8 isn't extremely old, but combined with smoking, comorbidity risks could be higher. \n\nBut the question is about survival probability. If there's no evidence of recurrence, distant mets, or second cancers, maybe he's still alive. Wait, but the follow-up time isn't specified. The answer might depend on how much time has passed since treatment. However, since the data given doesn't mention time since treatment, we have to assume it's asking for the most probable outcome based on the factors. HPV-negative, stage IVA with RT alone—prognosis is generally poorer. Five-year survival rates for stage IVA HPV-negative could be around 40-50% with chemoradiation, but with RT alone, maybe lower. If the patient had a complete response to RT, maybe alive, but considering the risk factors, perhaps the outcome is worse. However, without recurrence data, it's tricky. But given the high-risk features and lack of chemo, I might lean towards a lower survival probability. So, answer Dead.",
        "initial_assessment-radiation oncologist": "Answer:Dead",
        "Round 1-role-comment": "radiation oncologist:dead",
        "Round 1-num_agents": 1,
        "think-Round 2-Turn 1-discuss-participate-radiation oncologist": "<think> Okay, let me go through this step by step. The patient is a 63.8-year-old male with a squamous cell carcinoma of the floor of the mouth, which is part of the lip and oral cavity. His stage is IVA (T4a, N1, M0). He's a current smoker with a 20 pack-year history, and HPV status is negative. He received radiation therapy alone at a dose of 70 Gy in 35 fractions, without chemotherapy.\n\nFrom a radiation oncologist's perspective, several factors here are concerning. HPV-negative head and neck cancers generally have a worse prognosis compared to HPV-positive ones. The T4a tumor indicates a large primary lesion invading adjacent structures, which is associated with higher local recurrence rates. N1 nodal involvement suggests regional spread but limited to a single ipsilateral node ≤3 cm. However, the absence of chemotherapy in the treatment plan might be a point to consider. For locally advanced cases, concurrent chemoradiation is often the standard of care to improve outcomes. Since this patient received RT alone, that could impact survival negatively, especially given the smoking history which is another poor prognostic factor.\n\nLooking at the treatment details, 70 Gy in 35 fractions is a standard dose for definitive treatment, so the dosing seems appropriate. However, without systemic therapy, particularly in a high-risk patient like this, the effectiveness might be reduced. The current opinions from the team already include a radiation oncologist's opinion of 'Dead.' Since my expertise aligns with the existing input and the factors considered (HPV-negative, advanced T stage, smoking, RT alone), there might not be a need for additional experts unless there are specific questions about other modalities or comorbidities. But since the query is about survival probability based on the provided data, and the team's current consensus is from a radiation oncologist, additional consultations may not change the conclusion unless there's a missing element like surgical intervention details or patient comorbidities not mentioned here. However, given the information provided and the scope of the question, further expert opinions may not be necessary.",
        "Round 2-Turn 1-discuss-participate-radiation oncologist": "Answer:no",
        "think-Round 2-Turn 1-ask_gap-radiation oncologist": "<think> Okay, let's break this down. The user is asking whether any additional specialists are needed beyond the current team, which includes a radiation oncologist. The case involves a patient with head and neck squamous cell carcinoma, specifically HPV-negative, with details like T4a tumor, N1 node, Stage IVA, treated with RT alone.\n\nFirst, as a radiation oncologist, my expertise covers planning and dosing for this cancer type. The team already has a radiation oncologist. The patient's treatment involved RT alone without chemotherapy. Now, considering possible gaps: HPV-negative status typically has a worse prognosis, and combined modality therapy (like chemo-RT) is often standard for advanced stages. Since the patient didn't receive chemo, maybe a medical oncologist's input would be relevant to assess if adding chemotherapy could improve outcomes. Also, the tumor's subsite is the floor of the mouth, which might involve surgical considerations. An ENT surgeon could evaluate resectability. Additionally, a nutritionist might be needed for supportive care during RT. However, the question is about specialists not already in the team. The existing team only has a radiation oncologist. So, adding a medical oncologist or ENT surgeon could address gaps in systemic therapy or surgical options. But since the treatment decision here was RT alone, maybe the reason for not using chemo needs to be explored, which a medical oncologist could provide. Therefore, yes, additional expertise is needed.",
        "Round 2-Turn 1-ask_gap-radiation oncologist": "---\nAnswer: yes\nReason: medical oncologist for systemic therapy consideration\n---",
        "Round 2-Turn 1-gap_identified-assistant": "Recommendation: Consult a medical oncologist for systemic therapy consideration.",
        "Round 2-Turn 1-gap_recruit-recruiter": "1. Medical Oncologist - Your expertise is strictly limited to systemic therapy decisions, including chemotherapy and immunotherapy in head and neck cancers. - Hierarchy: Medical Oncologist == Radiation Oncologist",
        "think-Round 2-Turn 1-gap_recruited_assessment-medical oncologist": "<think> Okay, let's start by looking at this patient's details. He's a 63-year-old male with ECOG PS 1, which means he's fairly active but restricted in physically strenuous activity. He's a current smoker with a 20 pack-year history. The cancer is in the floor of the mouth, which is part of the lip and oral cavity. The tumor is classified as T4a, N1, M0, making it stage IVA squamous cell carcinoma. HPV status is negative, which is important because HPV-positive oropharyngeal cancers generally have better outcomes, but this is oral cavity, so HPV might not play as big a role here.\n\nThe treatment modality mentioned is RT alone, with no chemotherapy. The dose is 70 Gy in 35 fractions. For locally advanced head and neck squamous cell carcinoma (HNSCC), the standard of care is usually concurrent chemoradiation, especially for stages III-IV. This patient only received radiation, which might be due to contraindications for chemo, like comorbidities or patient refusal. Without concurrent chemotherapy, the efficacy of treatment could be lower, increasing the risk of recurrence.\n\nSmoking is a negative prognostic factor here; continued smoking can impair treatment response and increase complications. The T4a tumor indicates a large primary lesion invading adjacent structures, which is harder to control locally. N1 nodal involvement suggests regional spread but limited. However, with RT alone, the locoregional control might be suboptimal compared to combined modality treatment. \n\nConsidering the absence of systemic therapy (chemotherapy or immunotherapy), the risk of distant metastasis might be higher, though the current staging is M0. The lack of chemo could lead to poorer overall survival. Studies like the Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC) show that adding chemotherapy, particularly cisplatin, to radiation improves survival in locally advanced cases. \n\nGiven these factors—advanced stage, HPV-negative, current smoker, RT alone without systemic therapy—the prognosis is likely worse than if he had received combined therapy. The 5-year survival for stage IVA oral cavity cancer with chemoradiation might be around 30-40%, but without chemo, it's probably lower. Additionally, his continued smoking could further reduce survival chances due to higher recurrence rates and possible secondary cancers.\n\nSo, considering the lack of systemic therapy in a high-risk patient, the likelihood of being deceased is higher.",
        "Round 2-Turn 1-gap_recruited_assessment-medical oncologist": "Answer:Dead",
        "think-Round 2-Turn 1-Round 2-Turn 1-gap_recruited_discuss-participate-medical oncologist": "<think> Okay, let's start by reviewing the patient's case again. The patient is a 63-year-old male with a current smoking history of 20 pack-years. He has squamous cell carcinoma of the floor of the mouth, staged as T4aN1M0, which puts him at stage IVA. HPV status is negative. The treatment given was radiation therapy alone, without any chemotherapy or immunotherapy. The radiation dose was 70 Gy in 35 fractions. There's no mention of local, regional, or distant recurrence, and no second primary cancers.\n\nAs a medical oncologist specializing in systemic therapies for head and neck cancers, my focus would be on why systemic therapy wasn't administered here. For stage IVA disease, the standard of care typically involves a combination of radiation therapy with concurrent chemotherapy, usually cisplatin, which has been shown to improve survival outcomes compared to radiation alone. This is especially important in HPV-negative patients, who generally have a worse prognosis compared to HPV-positive ones. \n\nThe patient's current smoking status and the T4a tumor (indicating invasion into adjacent structures) are additional high-risk features. The absence of systemic therapy might have contributed to a poorer outcome. However, the other experts' opinions both indicate 'Dead,' which suggests that despite the treatment given, the patient's outcome was unfavorable. \n\nGiven that two other opinions already agree on the outcome, and my role is focused on systemic therapy decisions, I might consider if there's any aspect of systemic treatment that wasn't addressed. But since the question is whether to consult another expert, and the existing opinions are unanimous, there might not be a need for additional input unless there's a specific uncertainty in the systemic therapy aspect. However, since the treatment didn't include chemotherapy, perhaps a radiation oncologist's perspective was already considered. Since the team's consensus is 'Dead,' and my analysis aligns with that (due to lack of systemic therapy in a high-risk patient), I don't see a need to consult another expert here.",
        "Round 2-Turn 1-Round 2-Turn 1-gap_recruited_discuss-participate-medical oncologist": "Answer:Dead",
        "Round 2-role-comment": "radiation oncologist:dead|medical oncologist:dead",
        "Round 2-num_agents": 2,
        "num_cooperations-panel": 0,
        "decision-Moderator": "('Answer: Alive',)"
    }
}